Global Natural Killer Cells Therapeutics Market Was Valued At $216.219 Million In 2018
Cell therapy, a new therapeutic approach that uses a patient's own immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. NK cells are the body's first line of defense against infections and diseases with an innate ability to rapidly seek and destroy abnormal cells.
Natural killer cells are large granular lymphocytes that respond quickly to a pathological challenge. In addition, they are responsible for producing immunoregulatory cytokines. Moreover, they act as an important component of the innate immune system of a human. The key role of NK cells is to generate an immune response against malignancies and viral infections.
The global natural killer cells therapeutics market
was valued at $216.219 million in 2018, and is projected to reach $626.769 million by 2025, registering a CAGR of 16.4% from 2018 to 2025. The applications covered in the study include cancer, gastrointestinal diseases and others.
The North America natural killer cells therapeutics market share accounted for the highest share 52.4% in 2018 and is expected to continue its dominance throughout the forecast period. This is attributed to significant increase in prevalence of cancer in this region. However, the Asia market is anticipated to grow at the fastest pace, owing to increase in number of patients suffering from cancer, surge in geriatric population, and improvement in healthcare facilities. However, the complexity in regulatory frameworks regarding the approval of immunotherapy is expected to hamper the market growth.
NK cell therapeutics has promising applications in various research institutes. Various ongoing research activities such as NK cells & immunological memory improvements, stress-induced self-recognition, and cell-based therapies are currently in progress. Moreover, certain immuno-monitoring studies are being performed for determining the usage of NK cells. In hospitals, natural killer cell therapies are used to treat cancers using genetic engineering.
Major players operating in the market include Nektar Therapeutics, Innate Pharma SA, Affimed, Chipscreen Biosciences, Fate Therapeutics, Glycostem Therapeutics, Dragonfly Therapeutics, Kiadis Pharma, NantWorks, Nkarta Therapeutics, Fortress Biotech and etc.